Report Overview

The Kenya dermatological drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

With the increase in life expectancy and gradual rise in the aging population in Kenya, dermatological care is likely to receive particular attention. As people age, the risk of developing skin-related disorders increases, due to factors, such as changes in the connective tissue, reduction in the skin's strength and elasticity, and reduction in secretions from sebaceous glands. Skin conditions pose a significant threat to patients well-being, mental health, ability to function, and social participation. Skin diseases have seriously impact on peoples quality of life, causing productivity loss at work and other places, and discrimination due to disfigurement.



Market Drivers

The market is majorly driven by the rising burden of dermatology diseases. The factors responsible for the development of skin diseases include aging, climatic conditions, stress, auto-immune response, socioeconomic status, personal habits and genetic. Acne is the most common skin condition among young population and an increasingly physical appearance conscious youths is a fuelling factor for the market growth. Moreover, according to the Global Burden of Disease (GBD), skin diseases remain to be the important cause of nonfatal disease burden, thereby fuelling market demand.

The increasing incidence of dermatological diseases and increasing levels of awareness-related disease progression, etiology, and available therapies are leading to a high growth of dermatological drugs.

However, the side effects caused by several drugs are restraining market growth. Some of the products are withdrawn from the market due to serious side effects. Decline in the number dermatological consultations because of lockdown measures due to the COVID-19 outbreak may also hamper the growth of dermatological drug market.